Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-17 · accession 0001079973-26-000332 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-17 | STLN | Virnich Daniel | CEO | J - Other | $3.59 | -11.8K | 1.79M | -0.7% | -$42.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | J | D | 11,834 | $3.59 | 1,788,150 | D | — | — |